ABSTRACT
Objective To investigate the clinical significance of serum procalcitonin(PCT)and B-type natri-uretic peptide(BNP)before and after fluid resuscitation in patients with septic shock.Methods A total of 62 patients with septic shock were selected from January to December in 2015.The patients with arterial blood gas,24 hours of cumulative resuscitation fluid and the time of resuscitation were monitored and recorded.PCT and BNP levels were detected.Results The resuscitation fluid was(7 899.31 ± 1 337.64)mL and the time of resuscitation was(19.07 ± 5.64)h in the treatment of body fluid resuscitation in 62 patients.There were sig-nificant differences in pH,Na+,Cl-,PCT and BNP values before and after treatment,the differences were sta-tistical significant(P<0.05).There was a negative correlation between serum PCT and 24% cumulative ser-um(r= -0.956,P<0.05).Conclusion The levels of serum BNP and PCT in patients with septic shock were closely related to the disease,and can be used to monitor the therapeutic efficacy in patients with septic shock.
ABSTRACT
BACKGROUND: Several studies have focused on the association between the lipid-lowering efficacy of statins and the SLCO1B1 c.521T>C polymorphism; however, the results are conflicting. The effects of statins show significant variability between individuals. This meta-analysis aimed to investigate the effects of the SLCO1B1 c.521T>C polymorphism on the lipid-lowering effects of statins. METHODS: We systematically searched PubMed and Web of Science to screen relevant studies. Meta-analysis was performed to identify the association between SLCO1B1 c.521 polymorphisms and the lipid-lowering effects of statinson the basis of the standard mean difference (SMD) and 95% confidence intervals (CIs). Additionally, we checked for heterogeneity (I 2) among studies and evidence of publication bias. We obtained eight studies including 2,012 wild genotype (T/T) and 526 variant genotype (T/C and C/C) cases. RESULTS: No significant difference was observed in the lipid-lowering efficacy of statins between the wildand variant genotypes of SLCO1B1, with a pooled SMD of 0.03 (95% CI: -0.07-0.13). Furthermore, there was no significant effect in the meta-analyses of the variant heterozygote, homozygote, and Chinese populations. Subgroup meta-analysis indicated that the timerequired for the statin to take effectdid notsignificantly affect the association between lipid-lowering efficacy of statins and SLCO1B1 c.521T>C polymorphism. However, thewild genotype improved the lipid-lowering efficacy of simvastatin with a pooled SMD of -0.26 (95% CI: -0.47- -0.05). CONCLUSIONS: No significant association was detected between the lipid-lowering efficacy of statins and the SLCO1B1 c.521T>C polymorphism, with the exception of simvastatin.